Immunome (IMNM)
(Delayed Data from NSDQ)
$14.99 USD
-0.30 (-1.96%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $14.99 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Income Statements
Fiscal Year end for Immunome, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 14 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 14 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 124 | 37 | 25 | 12 | 10 |
Income After Depreciation & Amortization | -110 | -37 | -25 | -12 | -10 |
Non-Operating Income | 3 | 0 | 1 | -6 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -107 | -37 | -25 | -18 | -10 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -107 | -37 | -25 | -18 | -10 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -107 | -37 | -25 | -18 | -10 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -109 | -36 | -24 | -12 | -10 |
Depreciation & Amortization (Cash Flow) | 0 | 1 | 1 | 1 | 1 |
Income After Depreciation & Amortization | -110 | -37 | -25 | -12 | -10 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 19.84 | 12.13 | 11.54 | 3.39 | NA |
Diluted EPS Before Non-Recurring Items | -1.31 | -3.09 | -2.14 | -3.62 | NA |
Diluted Net EPS (GAAP) | -5.38 | -3.09 | -2.14 | -5.26 | -9.55 |
Fiscal Year end for Immunome, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 2.36 | 1.03 | 3.83 | 3.57 | 4.26 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 2.36 | 1.03 | 3.83 | 3.57 | 4.26 |
SG&A, R&D, and Dept/Amort Expenses | 42.38 | 133.33 | 17.68 | 8.20 | 10.04 |
Income After SG&A, R&D, and Dept/Amort Expenses | -40.02 | -132.30 | -13.85 | -4.63 | -5.78 |
Non-Operating Income | 3.89 | 2.81 | 2.02 | 0.29 | 0.22 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -36.12 | -129.49 | -92.63 | -4.35 | -5.56 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -36.12 | -129.49 | -92.63 | -4.35 | -5.56 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -36.12 | -129.49 | -92.63 | -4.35 | -5.56 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 59.94 | 51.54 | 21.95 | 12.20 | 12.20 |
Diluted EPS Before Non-Recurring Items | -0.49 | -0.34 | -0.54 | -0.36 | -0.46 |
Diluted Net EPS (GAAP) | -0.60 | -2.51 | -4.21 | -0.36 | -0.46 |